{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:32:55Z","timestamp":1790609575823,"version":"4.1.0"},"reference-count":86,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>mRNA vaccines have emerged as an optimistic technological platform for vaccine innovation in this new scientific era. mRNA vaccines have dramatically altered the domain of vaccinology by offering a versatile and rapid approach to combating infectious diseases and virus-induced cancers. Clinical trials have demonstrated efficacy rates of 94\u201395% in preventing COVID-19, and mRNA vaccines have been increasingly recognized as a powerful vaccine platform. Although mRNA vaccines have played an essential role in the COVID-19 pandemic, they still have several limitations; their instability and degradation affect their storage, delivery, and over-all efficiency. mRNA is typically enclosed in a transport mechanism to facilitate its entry into the target cell because it is an unstable and negatively charged molecule. For instance, mRNA that is given using lipid-nanoparticle-based vaccine delivery systems (LNPs) solely enters cells through endocytosis, establishing an endosome without damaging the cell membrane. The COVID-19 pandemic has accelerated the development of mRNA vaccine platforms used to treat and prevent several infectious diseases. This technology has the potential to change the future course of the disease by providing a safe and effective way to combat infectious diseases and cancer. A single-stranded genetic sequence found in mRNA vaccines instructs host cells to produce proteins inside ribosomes to elicit immunological responses and prepare the immune system to fight infections or cancer cells. The potential applications of mRNA vaccine technology are vast and can lead to the development of a preferred vaccine pattern. As a result, a new generation of vaccinations has gradually gained popularity and access to the general population. To adapt the design of an antigen, and even combine sequences from different variations in response to new changes in the viral genome, mRNA vaccines may be used. Current mRNA vaccines provide adequate safety and protection, but the duration of that protection can only be determined if further clinical research is conducted.<\/jats:p>","DOI":"10.3390\/medsci12020028","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T07:56:11Z","timestamp":1716364571000},"page":"28","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5685-6049","authenticated-orcid":false,"given":"Lakshmi Venkata Simhachalam","family":"Kutikuppala","sequence":"first","affiliation":[{"name":"Department of General Surgery, Dr. YSR University of Health Sciences, Vijayawada 520008, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8289-4869","authenticated-orcid":false,"given":"Islam","family":"Kourampi","sequence":"additional","affiliation":[{"name":"Department of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9136-3370","authenticated-orcid":false,"given":"Ramya S. D.","family":"Kanagala","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dr. KNR University of Health Sciences, Warangal 506007, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5330","authenticated-orcid":false,"given":"Priyadarshini","family":"Bhattacharjee","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Harsha","family":"Boppana","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.omtm.2019.10.015","article-title":"Nanoparticles versus dendritic cells as vehicles to deliver mRNA encoding multiple epitopes for immunotherapy","volume":"16","author":"Creusot","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Xu, S., Yang, K., Li, R., and Zhang, L. (2020). Mrna vaccine era\u2014Mechanisms, drug platform and clinical prospection. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186582"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Cagigi, A., and Lor\u00e9, K. (2021). Immune responses induced by mRNA vaccination in mice, monkeys and humans. Vaccines, 9.","DOI":"10.3390\/vaccines9010061"},{"key":"ref_7","unstructured":"Pascolo, S. (2008). Toll-Like Receptors (TLRs) and Innate Immunity, Springer."},{"key":"ref_8","first-page":"e16197","article-title":"HIV and Messenger RNA (mRNA) Vaccine","volume":"13","author":"Khalid","year":"2021","journal-title":"Cureus"},{"key":"ref_9","unstructured":"Rogers, J. (2023, November 16). NIH Launches Clinical Trial of Three mRNA HIV Vaccines [Internet]. National Institutes of Health (NIH), Available online: https:\/\/www.nih.gov\/news-events\/news-releases\/nih-launches-clinical-trial-three-mrna-hiv-vaccines."},{"key":"ref_10","unstructured":"Tabak, L. (2023, November 16). Encouraging First-in-Human Results for a Promising HIV Vaccine [Internet]. NIH Director\u2019s Blog, Available online: https:\/\/directorsblog.nih.gov\/2023\/06\/06\/encouraging-first-in-human-results-for-a-promising-hiv-vaccine."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: The results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Hu, X., Karthigeyan, K.P., Herbek, S., Valencia, S.M., Jenks, J.A., Webster, H., Miller, I.G., Connors, M., Pollara, J., and Andy, C. (2024). Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB\/MF59 Vaccine. J. Infect Dis., jiad593.","DOI":"10.1093\/infdis\/jiad593"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Scarpini, S., Morigi, F., Betti, L., Dondi, A., Biagi, C., and Lanari, M. (2021). Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice. Vaccines, 9.","DOI":"10.3390\/vaccines9060551"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1172\/JCI0214364","article-title":"Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors","volume":"109","author":"Heiser","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: An overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"LBA9503\u20133","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9503","article-title":"Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201\/KEYNOTE-942 trial","volume":"41","author":"Khattak","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_20","unstructured":"(2023, November 16). MSK mRNA Pancreatic Cancer Vaccine Trial Shows Promising Results|Memorial Sloan Kettering Cancer Center [Internet]. www.mskcc.org. Available online: https:\/\/www.mskcc.org\/news\/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.2174\/0929867329666220216110931","article-title":"Perspectives and Prospects on mRNA Vaccine Development for COVID-19","volume":"29","author":"Jin","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"ref_22","unstructured":"(2023, November 21). A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults \u226550 Years of Age\u2014Full Text View\u2014ClinicalTrials.gov [Internet], Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05330975."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"679344","DOI":"10.3389\/fimmu.2021.679344","article-title":"From COVID-19 to Cancer mRNA Vaccines: Moving from Bench to Clinic in the Vaccine Landscape","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Park, J.W., Lagniton, P.N.P., Liu, Y., and Xu, R.H. (2021). mRNA vaccines for COVID-19: What, why and how. Int. J. Biol. Sci., 17.","DOI":"10.7150\/ijbs.59233"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_26","first-page":"1","article-title":"The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism","volume":"76","author":"Amanpour","year":"2021","journal-title":"Arch. Razi Inst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2250022","DOI":"10.1002\/eji.202250022","article-title":"Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity","volume":"53","author":"Provine","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for Optimized mRNA Design Improves Stability and Immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/mt.2014.133","article-title":"A cationic nanoemulsion for the delivery of next-generation RNA vaccines","volume":"22","author":"Brito","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.nano.2015.11.001","article-title":"Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines","volume":"12","author":"Milona","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/acsinfecdis.9b00084","article-title":"Mannosylation of LNP Results in Improved Potency for Self-Amplifying RNA (SAM) Vaccines","volume":"5","author":"Goswami","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13273-021-00171-4","article-title":"Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency","volume":"18","author":"Kim","year":"2022","journal-title":"Mol. Cell. Toxicol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Gote, V., Bolla, P.K., Kommineni, N., Butreddy, A., Nukala, P.K., Palakurthi, S.S., and Khan, W. (2023). A Comprehensive Review of mRNA Vaccines. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032700"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Swetha, K., Kotla, N.G., Tunki, L., Jayaraj, A., Bhargava, S.K., Hu, H., Bonam, S.R., and Kurapati, R. (2023). Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines. Vaccines, 11.","DOI":"10.20944\/preprints202302.0142.v1"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Granados-Riveron, J.T., and Aquino-Jarquin, G. (2021). Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. Biomed. Pharmacother., 142.","DOI":"10.1016\/j.biopha.2021.111953"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.molmed.2013.09.002","article-title":"Challenges and advances towards the rational design of mRNA vaccines","volume":"19","author":"Pollard","year":"2013","journal-title":"Trends Mol. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ajps.2021.02.005","article-title":"Advances of mRNA vaccines for COVID-19: A new prophylactic revolution begins","volume":"16","author":"Weng","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/bs.ircmb.2022.04.011","article-title":"Advances in mRNA vaccines","volume":"372","author":"Li","year":"2022","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"896958","DOI":"10.3389\/fimmu.2022.896958","article-title":"Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"da Silva, M.K., Campos, D.M.O., Akash, S., Akter, S., Yee, L.C., Fulco, U.L., and Oliveira, J.I.N. (2023). Advances of Reverse Vaccinology for mRNA Vaccine Design against SARS-CoV-2: A Review of Methods and Tools. Viruses, 15.","DOI":"10.3390\/v15102130"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.ymthe.2022.02.016","article-title":"COVID-19 mRNA vaccines: Platforms and current developments","volume":"30","author":"Szabo","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: Principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.vaccine.2020.11.054","article-title":"New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates","volume":"39","author":"Ura","year":"2021","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jconrel.2022.03.032","article-title":"mRNA vaccines for COVID-19 and diverse diseases","volume":"345","author":"Hussain","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11095-021-03015-x","article-title":"Nanoparticle-Mediated Cytoplasmic Delivery of Messenger RNA Vaccines: Challenges and Future Perspectives","volume":"38","author":"Wu","year":"2021","journal-title":"Pharm. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_51","first-page":"51","article-title":"RNA therapeutics: Advances and challenges in the development of nucleic acid drugs","volume":"23","author":"Guevara","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"ref_52","first-page":"1260","article-title":"Overcoming the stability challenge of mRNA vaccines","volume":"27","author":"Li","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_53","first-page":"101260","article-title":"Engineering lipid nanoparticles for mRNA delivery","volume":"40","author":"Zhang","year":"2022","journal-title":"Nano Today"},{"key":"ref_54","first-page":"83","article-title":"Stable mRNA vaccine delivery using lipids","volume":"342","author":"Allen","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_55","first-page":"166","article-title":"Improving the thermostability of mRNA vaccines","volume":"341","author":"Chen","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_56","first-page":"263","article-title":"Stability and delivery challenges of mRNA vaccines: A review","volume":"14","author":"Lallana","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref_57","first-page":"491","article-title":"Strategies to improve mRNA stability and translation efficiency for efficient protein synthesis","volume":"337","author":"Li","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_58","first-page":"183","article-title":"Challenges and opportunities in mRNA vaccine delivery","volume":"345","author":"Loomis","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_59","first-page":"29","article-title":"Rational design of modified nucleosides for enhancing mRNA stability","volume":"66","author":"Feng","year":"2023","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_60","first-page":"252","article-title":"Development and clinical translation of approved mRNA vaccines","volume":"73","author":"Kaczmarek","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_61","first-page":"92","article-title":"Towards stable and efficient mRNA vaccines\u2014Successes and challenges","volume":"10","author":"Vogel","year":"2022","journal-title":"Vaccines"},{"key":"ref_62","first-page":"57","article-title":"Stability challenges and formulation strategies for RNA therapeutics","volume":"23","author":"Riedmann","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"ref_63","first-page":"91","article-title":"mRNA vaccine delivery using lipids with innate immune-activating potential","volume":"22","author":"Reichmuth","year":"2022","journal-title":"Nano Lett."},{"key":"ref_64","first-page":"114427","article-title":"Strategies to improve the stability of mRNA vaccines: From formulation design to delivery systems","volume":"189","author":"Chen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Liu, T., Liang, Y., and Huang, L. (2021). Development and Delivery Systems of mRNA Vaccines. Front. Bioeng. Biotechnol., 9.","DOI":"10.3389\/fbioe.2021.718753"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: Ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Wang, Y.S., Kumari, M., Chen, G.H., Hong, M.H., Yuan, J.P., Tsai, J.L., and Wu, H.C. (2023). mRNA-based vaccines and therapeutics: An in-depth survey of current and upcoming clinical applications. J. Biomed. Sci., 30.","DOI":"10.1186\/s12929-023-00977-5"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1186\/s12967-023-04724-0","article-title":"Advancing personalized medicine in brain cancer: Exploring the role of mRNA vaccines","volume":"21","author":"Lin","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Eljilany, I., Castellano, E., and Tarhini, A.A. (2023). Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field. Cancers, 15.","DOI":"10.3390\/cancers15164125"},{"key":"ref_71","first-page":"682","article-title":"333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program","volume":"14","author":"Palmer","year":"2020","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"102448","DOI":"10.1016\/j.eclinm.2024.102448","article-title":"The safety and immunogenicity of vaccines administered to pregnant women living with HIV: A systematic review and meta-analysis","volume":"69","author":"Nakabembe","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e164946","DOI":"10.1172\/JCI164946","article-title":"Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease","volume":"133","author":"Woolsey","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2020.06.011","article-title":"Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)","volume":"490","author":"Chen","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e30319","DOI":"10.1002\/pbc.30319","article-title":"Gene therapy in sickle cell disease: Attitudes and informational needs of patients and caregivers","volume":"70","author":"Sharma","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40290-021-00417-5","article-title":"Delivery Strategies for mRNA Vaccines","volume":"36","author":"Ramachandran","year":"2022","journal-title":"Pharm. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Wei, J., and Hui, A.-M. (2022). The delivery of mRNA vaccines for therapeutics. Life, 12.","DOI":"10.3390\/life12081254"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Miao, J., Gao, P., Li, Q., He, K., Zhang, L., Wang, J., and Huang, L. (2021). Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011227"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e08934","DOI":"10.1016\/j.heliyon.2022.e08934","article-title":"Liposome-polymer complex for drug delivery system and vaccine stabilization","volume":"8","author":"Sriwidodo","year":"2022","journal-title":"Heliyon"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles\u2014From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"103553","DOI":"10.1016\/j.jddst.2022.103553","article-title":"Lipid nanoparticles in the development of mRNA vaccines for COVID-19","volume":"74","author":"Wilson","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13223-022-00750-7","article-title":"Myopericarditis following both BNT162b2 and NVX-CoV2373","volume":"18","author":"Ahmad","year":"2022","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Khan, A.A., Allemailem, K.S., Almatroodi, S.A., Almatroudi, A., and Rahmani, A.H. (2020). Recent strategies towards the surface modification of liposomes: An innovative approach for different clinical applications. 3 Biotech, 10.","DOI":"10.1007\/s13205-020-2144-3"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2202688","DOI":"10.1002\/adhm.202202688","article-title":"Polymer-Based mRNA Delivery Strategies for Advanced Therapies","volume":"12","author":"Yang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"100766","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today"}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/12\/2\/28\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:46:23Z","timestamp":1760107583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/12\/2\/28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":86,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["medsci12020028"],"URL":"https:\/\/doi.org\/10.3390\/medsci12020028","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]}}}